Oral News and Research

RSS

Clinical trial to treat Female Orgasmic Disorder

Columbia University School of Nursing is the only site in New York State, and one of only 30 international sites selected to participate in a clinical trial to treat Acquired Female Orgasmic Disorder.

30 Apr 2013

FDA approves Octapharma USA's BLA for octaplex

The U.S. Food and Drug Administration has accepted Octapharma USA's Biological License Application for octaplex.

30 Apr 2013

Merck, Pfizer sign collaboration agreement for development and commercialization of ertugliflozin

Merck & Co., Inc., known as MSD outside the United States and Canada, and Pfizer Inc. today announced that they have entered into a worldwide (except Japan) collaboration agreement for the development and commercialization of Pfizer's ertugliflozin (PF-04971729), an investigational oral sodium glucose cotransporter (SGLT2) inhibitor being evaluated for the treatment of type 2 diabetes.

From Pfizer, Inc. 30 Apr 2013

Dental problems create substantial burden

Over 40 million hours are lost each year due to dental problems and their treatment in the Canadian population, study findings indicate.

29 Apr 2013

Specific inflammatory pattern found in patients with pneumonia and COPD

Patients with community-acquired pneumonia on a background of chronic obstructive pulmonary disease have a different early inflammatory pattern than patients with CAP only, a prospective study shows.

29 Apr 2013

Osteomyelitis guidelines push pediatric care

US clinicians have demonstrated the benefits of multidisciplinary evidence-based guidelines for the treatment of children with osteomyelitis.

29 Apr 2013

Maruishi gains exclusive rights to develop, commercialize Cara Therapeutics' CR845 in Japan

Cara Therapeutics, Inc. and Maruishi Pharmaceutical Company, Ltd. today announced that they have entered into a License Agreement providing Maruishi with exclusive rights to develop, manufacture and commercialize Cara's lead analgesic drug candidate, CR845, for acute pain and uremic pruritus in Japan.

29 Apr 2013

Oramed to report results of T1DM oral insulin formulation at Diabetes Summit 2013

Oramed Pharmaceuticals Inc., a developer of oral delivery systems of drugs currently administered by injection, announced today that its abstract, entitled "Oral insulin capsules toward management of Type 1 diabetes mellitus," will be presented at the Global Technology Community Diabetes Summit 2013.

29 Apr 2013

Transgene announces pre-clinical data of TG1050 for treatment of chronic hepatitis B infection

Transgene SA, a biopharmaceutical company that develops targeted immunotherapy products to treat major unmet medical needs in cancer and chronic infectious diseases, announced pre-clinical data obtained with its novel immunotherapeutic, TG1050, to treat chronic hepatitis B infection.

29 Apr 2013

Cempra demonstrates solithromycin's potential against urogenital infections at ECCMID

Cempra, Inc., a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infections, today announced that it will present data at the European Congress of Clinical Microbiology and Infectious Diseases in Berlin, demonstrating solithromycin's potential to treat urogenital infections and combat challenging pathogens such as enterococci and Legionella pneumophila.

29 Apr 2013

Practical guidelines on the use of new oral anticoagulants

A practical guide on the use of the new oral anticoagulants has been produced by the European Heart Rhythm Association of the European Society of Cardiology.

29 Apr 2013

Metabolic risk factors in overweight children linked with mild artery wall stiffness

Metabolic disorders, such as excess abdominal fat, raised blood pressure, higher levels of insulin, glucose and triglycerides and lower levels of the beneficial HDL cholesterol can be found in children as young as 6 to 8 years of age, according to a study carried out at the University of Eastern Finland.

26 Apr 2013

Cempra reports net loss of $10.3 million in first quarter 2013

Cempra, Inc., a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the first quarter ended March 31, 2013.

26 Apr 2013

Studies demonstrate encouraging results for new direct-acting antiviral agents

New data from a number of clinical trials presented for the first time at the International Liver Congress- 2013 demonstrate encouraging results in the use of new direct-acting antiviral agents (DAAs) for the treatment of hepatitis C.

25 Apr 2013

Perosphere, Daiichi Sankyo sign clinical trial agreement

Perosphere Inc. and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that they have entered into a clinical trial agreement under which Daiichi Sankyo will support and co-sponsor a phase 1 clinical study testing the safety, tolerability and effectiveness of PER977 to reverse the anticoagulant activity of edoxaban, Daiichi Sankyo's investigational oral, once-daily, direct factor Xa-inhibitor.

25 Apr 2013

Acucela begins phase 2b/3 clinical trial of emixustat hydrochloride to treat GA associated with dry AMD

Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for sight threatening eye diseases, today announced that a phase 2b/3 clinical trial investigating emixustat hydrochloride in subjects with geographic atrophy associated with dry age-related macular degeneration has been initiated.

25 Apr 2013

WHO highlights threat of antimalarial drug resistance in Greater Mekong subregion

On World Malaria Day, 25 April, WHO recognizes significant accomplishments in preventing and controlling malaria, including in high-burden countries in sub-Saharan Africa, but highlights the threat of antimalarial drug resistance in south-east Asia's Greater Mekong subregion, where an emergency response is now being launched.

25 Apr 2013

Roundup: Calif. health care cuts attract opponents; Health law means fewer hours for Va. community college instructors

In the health care world, there's not a whole lot that insurers, doctors and union workers all agree on. But a new coalition of powerful Capitol players from all three groups is hoping to reverse recent budget cuts, pushed by Gov. Jerry Brown, to those who provide care to the poorest Californians.

25 Apr 2013

Convergence starts Phase II proof of concept study with CNV2197944 in pain associated with PHN

Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines for the treatment of chronic pain, today announces that it has started a Phase II proof of concept study with CNV2197944 in pain associated with post-herpetic neuralgia.

24 Apr 2013

Opinion pieces address polio eradication goal to be discussed at Global Vaccine Summit

Public and private sector representatives will meet this week in Abu Dhabi at the Global Vaccine Summit, hosted by His Highness General Sheikh Mohamed bin Zayed bin Sultan Al Nahyan, Crown Prince of Abu Dhabi, in partnership with U.N. Secretary-General Ban Ki-moon and Bill Gates, co-chair of the Bill & Melinda Gates Foundation.

24 Apr 2013

Oral News and Research

Clinical trial to treat Female Orgasmic Disorder

FDA approves Octapharma USA's BLA for octaplex

Merck, Pfizer sign collaboration agreement for development and commercialization of ertugliflozin

Dental problems create substantial burden

Specific inflammatory pattern found in patients with pneumonia and COPD

Osteomyelitis guidelines push pediatric care

Maruishi gains exclusive rights to develop, commercialize Cara Therapeutics' CR845 in Japan

Oramed to report results of T1DM oral insulin formulation at Diabetes Summit 2013

Transgene announces pre-clinical data of TG1050 for treatment of chronic hepatitis B infection

Cempra demonstrates solithromycin's potential against urogenital infections at ECCMID

Practical guidelines on the use of new oral anticoagulants

Metabolic risk factors in overweight children linked with mild artery wall stiffness

Cempra reports net loss of $10.3 million in first quarter 2013

Studies demonstrate encouraging results for new direct-acting antiviral agents

Perosphere, Daiichi Sankyo sign clinical trial agreement

Acucela begins phase 2b/3 clinical trial of emixustat hydrochloride to treat GA associated with dry AMD

WHO highlights threat of antimalarial drug resistance in Greater Mekong subregion

Roundup: Calif. health care cuts attract opponents; Health law means fewer hours for Va. community college instructors

Convergence starts Phase II proof of concept study with CNV2197944 in pain associated with PHN

Opinion pieces address polio eradication goal to be discussed at Global Vaccine Summit

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News